

Clinically meaningful therapy with objective measures for psychiatry – that no one else has.

Highlights



- ✓ Unmatched accuracy in objective quantification of psychological stress at scale
- ✓ Differentiated Trojan horse GTM with P/M fit
- ✓ Versatile & clinically validated mobile health platform
- √ Team deeply experienced in healthcare, neuroscience, and business

Open Pre A (\$700K USD raised to date)

Team





Dr Bechara Saab, CEO & Chief Scientist

- Principal Investigator, Zurich Psychiatry Hospital
- Canadian W.E.F. "Future World Leader"
- 50+ peer-reviewed pubs; 2,000+ citations); 80+ talks worldwide
- Fellow, Royal Society of Medicine
- 3rd time founder & CEO; 1 exit; 2 still thriving
- PhD, Neuroscience, Mt. Sinai Hospital, Toronto



Jon Brilliant, CFO

- CFO, of Welldoc (raised \$50m+; lead deals w/ AstraZeneca, Sanofi)
- Co-founder and CFO, Bigfoot Biomedical (sold to Abbott, \$370m)
- Senior Advisor at Merck Global Healthcare Fund
- Co-founder, Managing Director, CFO of Atelier Group (\$65m fund)
- Juris Doctor, High Honours, Duke University



Mark Thoburn, Chief of Content

- Successful print and film journalist
- Directed 15 feature docs in 9 countries for the CBC
- Certified in Mindfulness-Based Stress Reduction
- 2017 Ontario Brain Institute Neurotech "ONtrepreneur"
- Master of Journalism, UBC



Michael Meissner, Growth Advisor

- Healthcare strategy
- · Former GM, Medtronic & CTO, Sanofi
- Former Chairman, Board of Directors, Scrum Alliance



Prof Linda Carlson, Clinical Partner

- Cancer patient understanding & access
- Professor of Psychosocial Oncology at UofC
- Enbridge Research Chair & Clinical Psychologist
- Author, med. manual Mindfulness-based Cancer Recovery



Prof Alex Wong, Technology Partner

- · Digital biomarker oversight
- Canada Research Chair of Al and Medical Imaging
- Professor of Systems Design Engineering at UofW
- Founder of DarwinAl

Plus another 10 full-time staff, 5 part-time staff, and over 100 contributing psychiatrists, clinical psychologists, and other qualified healthcare professionals and experts. At Mobio Interactive, we maintain a superstar in every seat: https://www.mobiointeractive.com/full-team

Market



Global mental healthcare expenditure:

\$1.8T

Accessible to Mobio's business model:

\$500B

Obtainable by Mobio at maturity:

\$50B

MOBIO

2027 ARR:

\$78M

Opportunity



Global Mental Health Crisis

It is no secret that demand for clinical mental health services far outstrips supply.





Demand: Everywhere

- The WHO estimates 1 in 8 people alive today need mental health services, and more than 1 in 2 will require mental health services at some point in their lives
- Youth are particularly in need, with suicide rising to the second leading cause of death between the ages of 10 and 25
- Many conditions have no approved therapy protocol



Supply: Missing data, scarce, expensive

- Without objective data, finding the right solution for a patient can take months or even years
- In-person psychotherapy is expensive and cannot scale to the demand
- Pharmacotherapy has limited efficacy and negative side-effects
- Non-clinical tools lack efficacy and integration into the healthcare economy, limiting access

Solution



AmDTx

Al native platform that <u>objectively</u> quantifies mental wellbeing in real time, supporting the workflow of healthcare professionals





Base platform for remote patient monitoring + patient & clinical decision support

- Objective measure of psychological stress without a wearable
- EMR-integrated remote patient monitoring and clinical decision support
- Patient wellbeing aid via 1,000+ medical-grade psychotherapy audio recordings in 7 languages
- Patient-specific personalisation via real time measures of efficacy



Prescription interventions:

- AmDTx can unlock indication-specific regulatory-cleared and fully reimbursed Class II SaMD interventions
- Each intervention is a clinically validated step-by-step psychotherapy course, engaged by patients asynchronously and on-demand
- Choice of intervention is made by a physician, via the clinic EMR integrated with AmDTx (single-click prescription mechanism)

Verticals



Laser focused on platform commercialisation via two complimentary verticals:



Health Systems Licensing

- Four major hospital clients signed and revenuegenerating (two in Canada, two in Singapore)
- Average ARR per hospital: \$55k USD
- Covers unlimited patient onboarding, backend integration with EHR
- Bespoke platform augmentation charged separately
- 2024 target revenues: \$500k (\$380k to date)



Remote Monitoring

- One key initial telehealth client signed and revenue generating (USD)
- Average MRR per patient: \$10 (can grow to \$200)
- Conservative estimate of 6 months of monitoring per patient
- Consistent, highly scalable MRR
- Simple to replicate
- 2024 target revenues: \$500k (\$10k to date)

These verticals are the fastest route to the most revenue. They strategically increase platform use by patients and physicians, which is important for additional verticals launching in 2025.

Existing Clients Examples








- Psychiatric teaching hospital in Toronto, plus 10 community centres across Ontario
- World-respected psychiatric research, incl. discovering the D2 dopamine receptor
- Licensing AmDTx to support psychiatric patients on waitlist, with >200 currently monitored and receiving care



CHEO (Children's Hospital of Eastern Ontario):

- Major tertiary children's hospital treating 260k patients annually with 2k physicians
- Global leader in "beyond hospital walls" program
- Licensing AmDTx to support paediatric psychiatric patients, with >50 currently monitored and receiving care



Neuroglympse:

- Neurology/psychiatry specialist telehealth provider in the USA
- Exceptionally innovative in the automation of patient data visualisation and procedure billing
- Distributing AmDTx for remote monitoring, with >150 patients currently reimbursed



Institute of Mental Health:

- Largest provider of mental health services in Singapore, with 50 wards and >2000 beds
- Only tertiary hospital in Singapore with psychiatric services
- Licensing AmDTx to support and monitor patients on waitlist, launching 24Q2 with 140 patients



Singapore General Hospital:

- Largest hospital in Singapore with 50 wards and >2000 beds and caring for 1 million patients annually
- Oldest and considered the "National" hospital of Singapore
- Licensing AmDTx to support and monitor patients on waitlist, launching 24Q2 with 60 patients

Client Testimonials





Prof. Dr. Alexander Daros, Centre for Addiction and Mental Health

"The potential of the Mobio Interactive platform is that people can do something that will help their mental wellbeing, while also feedback information to clinicians... to understand how that person is doing without having to subjectively ask them every week or every two days."



Prof. Dr. Gary Goldfield, Children's Hospital of Eastern Ontario

"We think DTx have the potential to remediate or address that massive disparity in supply and demand for services, as well as providing evidence-based care"




Brett Landrum, CEO, Neuroglympse


"What we love about the AmDTx platform is the unique combination of scientific rigor, versatility, customisation, and - most important for our patients - scalability."


Traction












Competitive Landscape





The <u>only</u> digital health platform that <u>objectively</u> quantifies mental wellbeing in real time while delivering clinically validated interventions without a wearable




Competitive Edge




A unique, large, high-quality dataset powerful enough to train AI to <u>objectively</u> quantify psychological states from a 30 s smartphone selfie

- HRV Breath Rate
- SpO₂ β-Carotene
- Bilirubin
 Microexpressions
- Melanin
 Facial Blood Distribution








Making Psychological Stress Objective



Psychological stress is the best available proxy for overall mental and physical health – when measured objectively – and thus a critical tool to guide clinical practice and personalise therapy for the population.

Using our unique dataset to train Al (self-developed 6-layer deep neural network)




12% greater accuracy and 15-fold lower error rate compared to the standard HRV algorithm


Table 3 Accuracy of stress prediction for classification DNN, chance and other methods

Method	Accuracy	MSE
Classification DNN	86%	ā
Prediction DNN	-	0.02
Chance	32%	3
Logistic Regression	77%	0.31
SVM	43%	4
HRV _{HIGH} /HRV _{LOW}	32%	1.45

Works for all skin tones



Proof of personalised care benefits from real world study with 2,876 patients in 80 countries



Clinical Partners





























































Clinical Trials (mostly RCTs)





Interventions (to commercialise only when the DTx market is sufficiently mature)






Financials



Revenue, Cost of Goods Sold, OpEx, EBITDA, Free Cash Flow, & Gross Margins




A Suite of Objective Tools for Psychiatry



We believe it is possible to objectively measure emotional valence and arousal.

Combined with objective stress, this creates an unbiased window into the mental wellbeing of a patient in real time, without the need for any medical hardware.



Next 24 Months



Platform Distribution

- 30 health systems onboarded by end of 2025
- Access >1m patients through 5k clinicians using the AmDTx platform for patient care and clinical decisions
- · Broad vector data creation

Technology Development


- · Triple access objective measuring stick for mental health
- Clinical validation across five languages within traumatic brain injury, psycho-oncology, post-partum depression, and paediatric eating disorders

Financials

 >1M ARR in 2024 via hospital AmDTx platform licensing and remote monitoring reimbursement codes with telehealth providers

Market Access

- Platform approvals for remote-CBT, remote-CCT, remote patient monitoring
- Single-click reimbursed prescriptions





Pre A – We'd love to have you with us.



We recently raised another \$700k from reputable VCs in health technologies, including:









We have >\$450k in revenue already in 2024 from respected hospitals and telehealth providers:



neuroglympse





We will use the Pre A capital to accelerate growth:

Platform licensing & reimbursed growth (1m)

Platform rebranding/redesign (500k) Deeptech & clinical (400k)

Together,
we will build the most
impactful and
profitable healthcare
platform in the world.





Objective quantification of stress in 30 s without a wearable (most accurate measure in the world).





Clinically validated therapy. Asynchronous, on-demand using any smartphone.





Precision psychiatry that scales to address the global mental health crisis.